335 related articles for article (PubMed ID: 23021204)
1. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases.
Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; O'Bryan-Tear CG; Thuresson M; Bolstad B; Bruland ØS
Clin Genitourin Cancer; 2013 Mar; 11(1):20-6. PubMed ID: 23021204
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial.
Hoskin P; Sartor O; O'Sullivan JM; Johannessen DC; Helle SI; Logue J; Bottomley D; Nilsson S; Vogelzang NJ; Fang F; Wahba M; Aksnes AK; Parker C
Lancet Oncol; 2014 Nov; 15(12):1397-406. PubMed ID: 25439694
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.
Parker CC; Pascoe S; Chodacki A; O'Sullivan JM; Germá JR; O'Bryan-Tear CG; Haider T; Hoskin P
Eur Urol; 2013 Feb; 63(2):189-97. PubMed ID: 23000088
[TBL] [Abstract][Full Text] [Related]
4. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
5. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program.
Heidenreich A; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Carles J; Wirth M; Miller K; Reeves J; Seger M; Nilsson S; Saad F
BMC Cancer; 2019 Jan; 19(1):12. PubMed ID: 30612558
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial.
Parker C; Finkelstein SE; Michalski JM; O'Sullivan JM; Bruland Ø; Vogelzang NJ; Coleman RE; Nilsson S; Sartor O; Li R; Seger MA; Bottomley D
Eur Urol; 2016 Nov; 70(5):875-883. PubMed ID: 27344296
[TBL] [Abstract][Full Text] [Related]
7. Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1/2 study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo J; Trandafir L; Wagner V; Li R; Nordquist LT
Prostate; 2019 Oct; 79(14):1683-1691. PubMed ID: 31442327
[TBL] [Abstract][Full Text] [Related]
8. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial.
Sartor O; Coleman R; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Widmark A; Johannessen DC; Hoskin P; James ND; Solberg A; Syndikus I; Vogelzang NJ; O'Bryan-Tear CG; Shan M; Bruland ØS; Parker C
Lancet Oncol; 2014 Jun; 15(7):738-46. PubMed ID: 24836273
[TBL] [Abstract][Full Text] [Related]
9. Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.
Nilsson S; Cislo P; Sartor O; Vogelzang NJ; Coleman RE; O'Sullivan JM; Reuning-Scherer J; Shan M; Zhan L; Parker C
Ann Oncol; 2016 May; 27(5):868-74. PubMed ID: 26912557
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA.
Sartor O; Hoskin P; Coleman RE; Nilsson S; Vogelzang NJ; Petrenciuc O; Staudacher K; Thuresson M; Parker C
Prostate; 2016 Jul; 76(10):905-16. PubMed ID: 27004570
[TBL] [Abstract][Full Text] [Related]
11. Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.
Nilsson S; Franzén L; Parker C; Tyrrell C; Blom R; Tennvall J; Lennernäs B; Petersson U; Johannessen DC; Sokal M; Pigott K; Yachnin J; Garkavij M; Strang P; Harmenberg J; Bolstad B; Bruland OS
Lancet Oncol; 2007 Jul; 8(7):587-94. PubMed ID: 17544845
[TBL] [Abstract][Full Text] [Related]
12. Alpha emitter radium-223 and survival in metastatic prostate cancer.
Parker C; Nilsson S; Heinrich D; Helle SI; O'Sullivan JM; Fosså SD; Chodacki A; Wiechno P; Logue J; Seke M; Widmark A; Johannessen DC; Hoskin P; Bottomley D; James ND; Solberg A; Syndikus I; Kliment J; Wedel S; Boehmer S; Dall'Oglio M; Franzén L; Coleman R; Vogelzang NJ; O'Bryan-Tear CG; Staudacher K; Garcia-Vargas J; Shan M; Bruland ØS; Sartor O;
N Engl J Med; 2013 Jul; 369(3):213-23. PubMed ID: 23863050
[TBL] [Abstract][Full Text] [Related]
13. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer.
Nilsson S; Strang P; Aksnes AK; Franzèn L; Olivier P; Pecking A; Staffurth J; Vasanthan S; Andersson C; Bruland ØS
Eur J Cancer; 2012 Mar; 48(5):678-86. PubMed ID: 22341993
[TBL] [Abstract][Full Text] [Related]
14. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
Jacene H; Gomella L; Yu EY; Rohren EM
Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
[TBL] [Abstract][Full Text] [Related]
15. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
16. Radium-223 dichloride for the treatment of bone metastatic castration-resistant prostate cancer: an evaluation of its safety.
Nilsson S
Expert Opin Drug Saf; 2015 Jul; 14(7):1127-36. PubMed ID: 26022669
[TBL] [Abstract][Full Text] [Related]
17. Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes: A Meta-analysis of Individual Patient Data From Randomized Clinical Trials.
Terrisse S; Karamouza E; Parker CC; Sartor AO; James ND; Pirrie S; Collette L; Tombal BF; Chahoud J; Smeland S; Erikstein B; Pignon JP; Fizazi K; Le Teuff G;
JAMA Oncol; 2020 Feb; 6(2):206-216. PubMed ID: 31830233
[TBL] [Abstract][Full Text] [Related]
18. Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases.
Sartor O; Heinrich D; Mariados N; Méndez Vidal MJ; Keizman D; Thellenberg Karlsson C; Peer A; Procopio G; Frank SJ; Pulkkanen K; Rosenbaum E; Severi S; Trigo Perez JM; Wagner V; Li R; Nordquist LT
Ann Oncol; 2017 Oct; 28(10):2464-2471. PubMed ID: 28961839
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomised, phase 2 trial.
James ND; Caty A; Borre M; Zonnenberg BA; Beuzeboc P; Morris T; Phung D; Dawson NA
Eur Urol; 2009 May; 55(5):1112-23. PubMed ID: 19042080
[TBL] [Abstract][Full Text] [Related]
20. Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials.
Rugo HS; Van Poznak CH; Neven P; Danielewicz I; Lee SC; Campone M; Chik JYK; Vega Alonso E; Naume B; Brain E; Siegel JM; Li R; Uema D; Wagner VJ; Coleman RE
Breast Cancer Res Treat; 2024 Apr; 204(2):249-259. PubMed ID: 38123789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
